Customers who struggle to afford the $1,000-plus list price for weight-loss drugs Zepbound and Wegovy can buy now and pay ...

Novo Nordisk said yesterday that it’s licensed a new obesity drug from The United Laboratories, a Chinese drugmaker.

Novo Nordisk is taking aim at Eli Lilly with a new obesity drug deal. Meanwhile, a survey shows doctors' perception of the ...

Novo Nordisk’s hopes of heralding a new era of obesity treatment with its next-generation CagriSema drug may be in doubt ...

Novo Nordisk, a Danish pharmaceutical company, has signed a major deal worth up to $2 billion for the rights to a new obesity ...

Obesity was tied with an increased risk of developing 16 health outcomes, a large longitudinal study showed. Risks correlated ...

A large majority of older Americans feel that health insurance—including Medicare—should cover anti-obesity medications, ...

The versions affected are called compounded medications, which have the same active ingredients as the name brands. The ...

Currently, there are six FDA approved weight loss medications. They include three GLP-1 receptor agonists -- liraglutide ...

Large-scale compounding facilities have to stop making tirzepatide, the main ingredient in blockbuster obesity drug Zepbound, ...

Compounding pharmacies have been allowed to essentially make a cheaper version of Eli Lilly's Zepbound, but they have to stop ...